

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1-57 (Canceled)

58. (Currently Amended) ~~The compound according to claim 1 which is a~~ A compound selected from the ~~following~~ group consisting of:

(S,S)-2-Ethoxy-3-[4-[3-(4'-(3-[4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-propyl)-2,2'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl]-propionic acid;

(S,S)-3-[4-[3-(4'-(3-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-propyl)-2,2'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl]-2-ethoxy-propionic acid;

(S,S)-2-Ethoxy-3-[4-[3-(4'-(3-[4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-propyl)-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl]-propionic acid;

(S,S)-3-[4-[3-(4'-(3-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-propyl)-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl]-2-ethoxy-propionic acid;

(S,S)-3-[3-Bromo-4-[3-(4'-(3-[2-bromo-4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-propyl)-2,2'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl]-2-ethoxy-propionic acid;

(S,S)-3-[3-Bromo-4-[3-(4'-(3-[2-bromo-4-(2-carboxy-2-ethoxy-ethyl)-phenoxy]-propyl)-2,2'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl]-2-ethoxy-propionic acid;

(S,S)-3-[3-Bromo-4-[3-(4'-[3-[2-bromo-4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-propyl]-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl]-2-ethoxy-propionic acid;

(S,S)-3-[3-Bromo-4-[3-(4'-[3-[2-bromo-4-(2-carboxy-2-ethoxy-ethyl)-phenoxy]-propyl]-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl]-2-ethoxy-propionic acid;

[4-(3-{4'-[3-(4-Methoxycarbonylmethoxy-3-methyl-phenylsulfanyl)-propyl]-2,2'-bis-trifluoromethyl-biphenyl-4-yl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid;

[4-(3-{4'-[3-(4-Methoxycarbonylmethoxy-3-methyl-phenylsulfanyl)-propyl]-3,3'-bis-trifluoromethyl-biphenyl-4-yl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid;

[4-(3-{4'-[3-(4-Carboxymethoxy-3-methyl-phenylsulfanyl)-propyl]-3,3'-bis-trifluoromethyl-biphenyl-4-yl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid;

(4-{2-[2-(3-{4-[2-(4-Methoxycarbonylmethoxy-3-methyl-phenylsulfanyl)-ethyl]-5-methyl-oxazol-2-yl)-phenyl]-5-methyl-oxazol-4-yl]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid;

(4-{2-[2-(3-{4-[2-(4-Carboxymethoxy-3-methyl-phenylsulfanyl)-ethyl]-5-methyl-oxazol-2-yl)-phenyl]-5-methyl-oxazol-4-yl]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid;

(S,S)-2-Ethoxy-3-[4-(2-[2-[4'-(4-{2-[4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-ethyl]-5-methyl-oxazol-2-yl)-biphenyl-4-yl]-5-methyl-oxazol-4-yl)-ethoxy)-phenyl]-propionic acid;

(S,S)-3-[4-(2-[2-[4'-(4-{2-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-ethyl]-5-methyl-oxazol-2-yl)-biphenyl-4-yl]-5-methyl-oxazol-4-yl)-ethoxy)-phenyl]-2-ethoxy-propionic acid;

(S,S)-2-Ethoxy-3-[4-(2-[3-(4-[2-[4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-ethyl]-5-methyl-oxazol-2-yl)-phenyl]-5-methyl-oxazol-4-yl)-ethoxy)-phenyl]-propionic acid; and  
(S,S)- 3-[4-(2-[2-[3-(4-[2-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-ethyl]-5-methyl-oxazol-2-yl)-phenyl]-5-methyl-oxazol-4-yl)-ethoxy)-phenyl]-2-ethoxy-propionic acid;  
or  
a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, racemic mixture, or any tautomeric forms.

59. (Currently Amended) ~~The compound according to claim 4~~ A compound which is selected from the following group consisting of:

(S,S)-2-Ethoxy-3-[4-[3-(4'-[3-[4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-propyl]-2,2'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl]-propionic acid isopropyl ester;  
(S,S)-2-Ethoxy-3-[4-[3-(4'-[3-[4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-propyl]-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl]-propionic acid isopropyl ester;  
(S,S)-3-[3-Bromo-4-[3-(4'-[3-[2-bromo-4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-propyl]-2,2'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl]-2-ethoxy-propionic acid isopropyl ester;  
(S,S)-3-[3-Bromo-4-[3-(4'-[3-[2-bromo-4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-propyl]-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl]-2-ethoxy-propionic acid isopropyl ester;  
[4-(3-[4'-[3-[4-Methoxycarbonylmethoxy-3-methyl-phenylsulfanyl]-propyl]-2,2'-bis-trifluoromethyl-biphenyl-4-yl)-propylsulfanyl]-2-methyl-phenoxy]-acetic acid methyl ester;

[4-(3-{4'-[3-(4-Carboxymethoxy-3-methyl-phenylsulfanyl)-propyl]-2,2'-bis-trifluoromethyl-biphenyl-4-yl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid;  
[4-(3-{4'-[3-(4-Methoxycarbonylmethoxy-3-methyl-phenylsulfanyl)-propyl]-3,3'-bis-trifluoromethyl-biphenyl-4-yl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid methyl ester;  
(4-{2-[2-(3-{4-[2-(4-Methoxycarbonylmethoxy-3-methyl-phenylsulfanyl)-ethyl]-5-methyl-oxazol-2-yl]-phenyl)-5-methyl-oxazol-4-yl]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid methyl ester;  
(S,S)-2-Ethoxy-3-[4-(2-{2-[4'-(4-{2-[4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-ethyl]-5-methyl-oxazol-2-yl]-biphenyl-4-yl]-5-methyl-oxazol-4-yl]-ethoxy)-phenyl]-propionic acid isopropyl ester; and  
(S,S)-2-Ethoxy-3-[4-(2-{2-[3-(4-{2-[4-(2-ethoxy-2-isopropoxycarbonyl-ethyl)-phenoxy]-ethyl]-5-methyl-oxazol-2-yl]-phenyl]-5-methyl-oxazol-4-yl]-ethoxy)-phenyl]-propionic acid isopropyl ester; or  
a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, racemic mixture, or any tautomeric forms.

60. (Canceled).

61. (Currently Amended) ~~The compound according to claim 4~~ A compound which is selected from the following group consisting of:

3-[4-(2-{2-[3-(4-{2-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-ethyl]-5-methyl-oxazol-2-yl]-phenyl]-5-methyl-oxazol-4-yl]-ethoxy)-phenyl]-2-ethoxy-propionic acid;  
(4-{2-[2-(3-{4-[2-(4-Carboxymethoxy-3-methyl-phenylsulfanyl)-ethyl]-5-methyl-oxazol-2-yl]-phenyl)-5-methyl-oxazol-4-yl]-ethylsulfanyl}-2-methyl-phenoxy)-acetic acid;

(4-{2-[2-(3-{4-[2-(4-Carboxymethoxy-3-methyl-phenoxy)-ethyl]-5-methyl-oxazol-2-yl}-phenyl)-5-methyl-oxazol-4-yl]-ethoxy}-2-methyl-phenoxy)-acetic acid;  
(4-{2-[2-(3-{4-[2-(4-Carboxymethoxy-phenoxy)-ethyl]-5-methyl-oxazol-2-yl}-phenyl)-5-methyl-oxazol-4-yl]-ethoxy}-phenoxy)-acetic acid;  
(4-{2-[2-(3-{4-[2-(4-Carboxymethoxy-phenylsulfanyl)-ethyl]-5-methyl-oxazol-2-yl}-phenyl)-5-methyl-oxazol-4-yl]-ethylsulfanyl}-phenoxy)-acetic acid;  
3-{4-{2-[2-(3-{4-[2-(4-(2-Carboxy-2-ethoxy-ethyl)-phenylsulfanyl)-ethyl]-5-methyl-oxazol-2-yl}-phenyl)-5-methyl-oxazol-4-yl]-ethylsulfanyl}-phenyl]-2-ethoxy-propionic acid;

3-{4-[3-(4'-{3-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-propyl]-2,2'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl]-2-ethoxy-propionic acid;  
3-{4-[3-(4'-{3-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-propyl]-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl]-2-ethoxy-propionic acid;  
3-{3-Bromo-4-[3-(4'-{3-[2-bromo-4-(2-carboxy-2-ethoxy-ethyl)-phenoxy]-propyl]-2,2'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl]-2-ethoxy-propionic acid;  
3-{3-Bromo-4-[3-(4'-{3-[2-bromo-4-(2-carboxy-2-ethoxy-ethyl)-phenoxy]-propyl]-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy]-phenyl]-2-ethoxy-propionic acid;  
[4-(3-(4'-{3-[4-Carboxymethoxy-3-methyl-phenylsulfanyl]-propyl]-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-propylsulfanyl)-2-methyl-phenoxy]-acetic acid;  
[4-(3-(4'-{3-[4-Carboxymethoxy-phenylsulfanyl]-propyl]-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-propylsulfanyl)-phenoxy]-acetic acid;  
[4-(3-(4'-{3-[4-Carboxymethoxy-phenoxy]-propyl]-3,3'-bis-trifluoromethyl-biphenyl-4-yl)-propoxy)-phenoxy]-acetic acid;

[4-(3-{4'-[3-(4-Carboxymethoxy-3-methyl-phenoxy)-propyl]-3,3'-bis-trifluoromethyl-biphenyl-4-yl}-propoxy)-2-methyl-phenoxy]-acetic acid;  
[4-(3-{4'-[3-(4-Carboxymethoxy-3-methyl-phenylsulfanyl)-propyl]-2,2'-bis-trifluoromethyl-biphenyl-4-yl}-propylsulfanyl)-2-methyl-phenoxy]-acetic acid;  
[4-(3-{4'-[3-(4-Carboxymethoxy-3-methyl-phenoxy)-propyl]-2,2'-bis-trifluoromethyl-biphenyl-4-yl}-propoxy)-2-methyl-phenoxy]-acetic acid; and  
3-[4-(2-{2-[4'-(4-{2-[4-(2-Carboxy-2-ethoxy-ethyl)-phenoxy]-ethyl)-5-methyl-oxazol-2-yl]-biphenyl-4-yl]-5-methyl-oxazol-4-yl}-ethoxy)-phenyl]-2-ethoxy-propionic acid;  
or  
a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, racemic mixture, or any tautomeric forms.

Claims 62 – 64. (Canceled)

65. (Currently Amended) A pharmaceutical composition comprising, as an active ingredient, at least one compound according to claim 4- 58 together with one or more pharmaceutically acceptable carriers or excipients.

66. (Currently Amended) A pharmaceutical composition according to claim 65 in unit dosage form, comprising from about 0.05 mg to about 1000 mg, ~~from about 0.1 to about 500 mg, or from about 0.5 mg to about 200 mg~~ of compound.

67. (Cancelled)

68. (Cancelled)

69. (Previously presented) A pharmaceutical composition according to claim 65 formulated for oral, nasal, transdermal, pulmonal, or parenteral administration.

Claims 70-73 (Canceled).

74. (New) A pharmaceutical composition comprising, as an active ingredient, at least one compound according to claim 59 together with one or more pharmaceutically acceptable carriers or excipients.

75. (New) A pharmaceutical composition according to claim 74 in unit dosage form, comprising from about 0.05 mg to about 1000 mg of compound.

76. (New) A pharmaceutical composition comprising, as an active ingredient, at least one compound according to claim 61 together with one or more pharmaceutically acceptable carriers or excipients.

77. (New) A pharmaceutical composition according to claim 76 in unit dosage form, comprising from about 0.05 mg to about 1000 mg of compound.